Blood plasma donated by COVID-19 survivors in the United States is helping develop treatments to fight the disease.
Early this year, scientists identified COVID-19 convalescent plasma (CCP) — blood plasma from people who have already cleared the virus — as a potential treatment. CCP is often rich in antibodies that when transferred to a patient with COVID-19 may help the recipient fight the virus.
The U.S. Department of Defense began collecting the plasma in mid-April and by mid-November had surpassed its goal of collecting 8,000 to 10,000 units. The ongoing military campaign has collected 10,745 units to help fight the disease. Roughly 3,000 survivors have donated plasma in the effort.
“I congratulate you for achieving thousands of units in such a short amount of time — that is no small feat,” Deputy Defense Secretary David L. Norquist said in a November 16 statement hailing both the donors and collectors of the plasma. “It is a testament to your hard work to conduct daily collections at blood donor centers and your willingness to venture into hot spots for mobile blood drivWhile researchers are still studying the use of CCP, Norquist reports, early findings show that CCP is “safe and promising” as a potential COVID-19 treatment. Collecting and researching CCP as a treatment for COVID-19 is part of wide-ranging U.S. efforts to end the global pandemic. Through Operation Warp Speed, the Trump administration is investing billions of dollars to accelerate the development, clinical trials, manufacture and distribution of vaccines.
The U.S. government has supported numerous COVID-19 vaccine candidates, including three that appear to be highly effective in clinical trials at preventing COVID-19. As many as 300 million doses of a vaccine could possibly be delivered by the end of 2020, Norquist said.